THE BOSUTINIB CASE TRUST BUT CHECK OUT

Bosutinib is a selective kinase inhibitor introduced in 2012 by Pfizer Co. for treatment of chronic myeloid leukemia. Bosutinib is widely used in medicine and basic research. Some information indicated that researchers purchasing Bosutinib from a wide range of sources may have unwittingly been using an isomer of Bosutinib instead of Bosutinib itself. The aim of the review is to describe this serious case of marketing as well as to outline possible reasons and consequences of this case.